Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease [0.03%]
达格列净对中重度慢性肾脏病患者尿酸水平的影响效力
Katsunori Yanai,Keiji Hirai,Taisuke Kitano et al.
Katsunori Yanai et al.
Aims: We investigated the efficacy of dapagliflozin, which is a sodium-glucose cotransporter 2 inhibitor, on uric acid (UA) in individuals with moderate-to-severe chronic kidney disease (CKD) (stage G3-4). ...
Effects of home-based exercise on physical function and health-related quality of life in older patients with pre-dialysis chronic kidney disease: a single-center randomized controlled trial [0.03%]
家庭锻炼对透析前期慢性肾脏病老年患者身体功能和健康相关生命质量影响的单中心随机对照试验
Aki Tabata,Hiroki Yabe,Takehide Katogi et al.
Aki Tabata et al.
Background: Exercise therapy is recommended for patients with chronic kidney disease (CKD), but evidence for its effectiveness in older adults with pre-dialysis CKD is limited. ...
Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors [0.03%]
促红细胞生成素或缺氧诱导因子脯氨酰羟化酶抑制剂初始应用时监测铁指标的依从性
Yoshihisa Miyamoto,Akira Okada,Yusuke Sasabuchi et al.
Yoshihisa Miyamoto et al.
Background: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have been used for the treatment of anemia in patients with chronic kidney disease not receiving dialysis since 2020. In September 2020, the Japa...
Impact of red blood cell transfusion timing and volume on biopsy-proven rejection: a single-center cohort study [0.03%]
红细胞输血时间和剂量对 biopsy 证实的排斥反应的影响：一项单中心队列研究
Kuniaki Inoue,Shunta Hori,Mitsuru Tomizawa et al.
Kuniaki Inoue et al.
Background: Perioperative red blood cell transfusion (RBCT) and immunosuppressive therapy are critical factors influencing the risk of kidney transplantation (KT) rejection. In this study, we examined how RBCT volume, tim...
Clinical factors associated with long-term renal outcomes in Japanese patients with IgA nephropathy presenting with nephrotic range proteinuria: a multicenter, retrospective, cohort study [0.03%]
日本系膜增生性肾小球肾炎患者大量蛋白尿的临床表现及长期肾脏转归：多中心回顾性队列研究
Tomohiro Saito,Yukihiro Wada,Takanori Shibata et al.
Tomohiro Saito et al.
Background: Patients with IgA nephropathy (IgAN) occasionally present with nephrotic range proteinuria (NRP), but the clinical features and long-term renal prognosis of patients with IgAN-related NRP (IgAN-NRP) with or wi...
Sedentary behavior as an emerging risk factor for chronic kidney disease: a narrative review [0.03%]
久坐行为被确认为慢性肾病的新风险因素：综述性文章
Shun Yoshikoshi,Keisei Kosaki,Koichiro Oka et al.
Shun Yoshikoshi et al.
Sedentary behavior (SB) has gained attention as one of the behavioral risk factors, independent of physical inactivity. Patients with chronic diseases, such as hypertension and type 2 diabetes, tend to have longer SB, and prolonged SB is re...
Correction: Estimated T50 calciprotein crystallization test in patients undergoing hemodialysis: Osaka Dialysis Complication Study (ODCS) [0.03%]
订正：透析患者的估算T50钙蛋白结晶试验：大阪透析并发症研究(ODCS)
Tetsuo Shoji,Daijiro Kabata,Yu Nagakura et al.
Tetsuo Shoji et al.
Published Erratum
Clinical and experimental nephrology. 2025 Sep 9. DOI:10.1007/s10157-025-02756-y 2025
Comparison of renal effects between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension and chronic kidney disease in Japan [0.03%]
日本未控制的高血压和慢性肾脏病患者中沙库必利/缬沙坦与噻嗪类利尿剂对肾功能影响的比较研究
Mari Sotozawa,Kyoji Chiba,Kazuo Kobayashi et al.
Mari Sotozawa et al.
Background: Sacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior to...
Combined effect of hyperhomocysteinemia and mild-to-moderate chronic kidney disease on mortality and cardiovascular events in the Japanese general population: the Yamagata (Takahata) study [0.03%]
高同型半胱氨酸血症与中度肾功能不全对日本一般人群死亡率和心血管事件的联合作用：山形（高畠）研究
Tomohiro Takehara,Yoichiro Otaki,Kai Matsuo et al.
Tomohiro Takehara et al.
Background: Hyperhomocysteinemia (HHcy) and chronic kidney disease (CKD) are risk factors for cardiovascular events and all-cause mortality. Although their coexistence may further amplify these risks, few studies have eva...
Sodium glucose co-transporter 2 inhibitors (SGLT2Is) effect on erectile dysfunction (ED) in patients with chronic kidney disease (CKD) [0.03%]
钠葡萄糖协同转运蛋白2抑制剂(SGLT2Is)对慢性肾脏病(CKD)患者勃起功能障碍(ED)的影响
Amr Mohamed Shaker,Nehal Kamal Rakha,Ahmed Keshk et al.
Amr Mohamed Shaker et al.
Background: ED is commonly encountered among male CKD patients. SGLT2Is were recently recommended as a universal treatment for CKD. It's hypothesized that the mechanism of action of SGLT2Is could be related to improving e...